UnknownPhase 3NCT04532229
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Principal Investigator
- Xiaojun YuanXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Intervention
- Nimotuzumab+CRT(concurrent IMRT and TMZ)(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 3-15 years · All sexes
- Timeline
- 2021 – 2023
Study locations (8)
- The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, China
- Xiangya Hospital of Centre-south University, Changsha, Hunan, China
- West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Peking Union Medical College Hospital, Beijing, China
- Xuanwu Hospital Capital Medical University, Beijing, China
- Shandong Cancer Hospital, Jinan, China
- Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04532229 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital